Investor profile
Portal Innovations
VC
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Portal Innovations is a venture development platform that delivers 'Crafted Capital' — seed capital, fully equipped wet/dry lab space, and seasoned management expertise — to science-driven, early-stage life sciences, medtech, and bioinformatics companies addressing underserved human health challenges. The firm curates and selects innovative companies founded by top-notch faculty and entrepreneurs at the nexus of therapeutics, AI, and medtech, surrounding them with the physical, human, and financial resources needed to reach commercial proof of concept and attract world-class Series A investors. Portal operates a national membership model across locations in Chicago, Providence, New Brunswick (NJ), and Houston, partnering closely with leading academic institutions such as the University of Chicago, Brown University, and UT Health to source university spinouts. Its market-based approach guides portfolio companies from seed through Series A, with the end goal of prosperous exits via acquisition or strategic partnership — exemplified by the acquisition of CrossBridge Bio by Eli Lilly in a deal worth up to $300M.
Notable quotes
“Innovation isn't stopping. It's just where is it going and how is it getting funded. You're going to see a greater distribution. Talent is distributing. If we look on a universal level, if the US is pulling back at that early stage, well, other countries are going in.”
“The patent cliff that faces big pharma — they need to be replenishing their pipeline. And thankfully one of the things that I think is driving the valuations is the transformative therapeutics being developed that are creating better outcomes for patients across a range of different therapeutic areas, including neurology, disease of the brain, cancer, autoimmune diseases.”
“What we really like about ClostraBio is the fact that they have been able to de-risk their technology and their lead asset to a point where they are less than 18 months from the clinic. There is not just a big market, but a very impactful opportunity right here.”
Team
Michael Schultz
Partner
Nancy Tyrrell
Principal
Monique Pierre Knighten
Partner
Derrell Porter
Partner (MD, MBA)
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Syntis | Series A | — | 2025-07-01 |
| Grove Biopharma | Series A | $30m | 2025-04-23 |
| March Biosciences | Series A | $28m | 2024-10-23 |
| CrossBridge Bio | Seed | — | 2024-11-04 |
| NOVABLOC (Synaptrix) | Series A | — | 2024-11-08 |
| Cardiosense | Series A | $15m | 2022-12-08 |
| ClostraBio | Series A | $4m | 2022-10-07 |
| Dimension Bio | Seed | — | — |
| Iterion Therapeutics | Seed | — | — |
| ARase Therapeutics | Seed | — | — |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| TMC Venture Fund | 2 |
| Hatteras Venture Partners | 2 |
| Mansueto Investments | 2 |
| Mission BioCapital | 1 |
| DCVC Bio | 1 |
| 4BIO Capital | 1 |
Fit check
Is Portal Innovations a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit